The Division of Rheumatology strives to understand more about scleroderma and systemic sclerosis through research. Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease.
|Basic Eligibility Criteria
|MINERAL; Microbiome and Neutrophil associated factors in Rheumatoid Arthritis and Autoimmune-related Interstitial Lung Disease
Melissa Griffith, MD
|An observational study to investigate the causes of chronic lung disease in rheumatoid arthritis and other autoimmune diseases
|1. At least 18 years old
2. Falls under one of the following criteria:
a. Diagnosis of scleroderma
b. Diagnosis of idiopathic pulmonary fibrosis (IPF) or interstitial pneumonia with autoimmune features (IPAF)
c. Diagnosis of RA with associated interstitial lung disease
d. Diagnosis of RA with previous lung abnormalities seen on lung scan
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length. A visit to determine an individuals eligibility may be required. A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.